Hybrid Immunity for COVID-19 in Bolivian Healthcare Workers
| dc.contributor.author | Raúl Copana Olmos | |
| dc.contributor.author | Nelva Guillen Rocha | |
| dc.contributor.author | Yercin Mamani | |
| dc.contributor.author | Gladys Rodriguez Alvarez | |
| dc.contributor.author | Angelica Ovando Campos | |
| dc.contributor.author | Carla Camacho Tufiño | |
| dc.coverage.spatial | Bolivia | |
| dc.date.accessioned | 2026-03-22T16:26:49Z | |
| dc.date.available | 2026-03-22T16:26:49Z | |
| dc.date.issued | 2022 | |
| dc.description | Citaciones: 1 | |
| dc.description.abstract | Introduction Vaccination is one of the pillars for the prevention of COVID-19 in healthcare workers (HCWs). The present study aims to determine the effectiveness of vaccination for COVID-19 as well as hybrid immunity in previously infected HCWs in a hospital in a developing country. Methods An observational study was carried out on health personnel with a complete COVID-19 vaccination schedule according to their previous infection status, with a follow-up period of 15 months. Results In this study, 335 subjects were enrolled, of which 32.8% had a previous infection with COVID-19. The safety of vaccines was determined by estimating the presence of adverse effects of vaccination and immunization (AEVI), with the first and second doses showing an incidence of 8.2% and 9.5% respectively, during the second and third waves. Around 5.7% of immunized personnel were sick and 8.4% in the fourth wave; the serum value of neutralizing antibodies was normal at 60.2% with no differences between vaccines (p=0.164). However, in personnel with hybrid immunity, there were normal levels of antibodies in 81.8% of cases (p= 0.023), fewer days of medical leave (6.4 days (standard deviation=1.4) (p=0.067)), higher immunoglobin values (p=0.011) and an insignificantly (p=0.248) lower rate of COVID-19 presentation. Conclusion Vaccination, when applied to people who previously acquired natural immunity, generates a hybrid immunity that is robust, and could have a longer duration, as well as greater efficacy for new COVID-19 variants of concern. | |
| dc.identifier.doi | 10.7759/cureus.27449 | |
| dc.identifier.uri | https://doi.org/10.7759/cureus.27449 | |
| dc.identifier.uri | https://andeanlibrary.org/handle/123456789/58289 | |
| dc.language.iso | en | |
| dc.publisher | Cureus, Inc. | |
| dc.relation.ispartof | Cureus | |
| dc.source | Hospital del Niño | |
| dc.subject | Medicine | |
| dc.subject | Vaccination | |
| dc.subject | Immunity | |
| dc.subject | Vaccination schedule | |
| dc.subject | Immunization | |
| dc.subject | Health care | |
| dc.subject | Incidence (geometry) | |
| dc.subject | Herd immunity | |
| dc.subject | Antibody | |
| dc.subject | Coronavirus disease 2019 (COVID-19) | |
| dc.title | Hybrid Immunity for COVID-19 in Bolivian Healthcare Workers | |
| dc.type | article |